Document is current
Any future updates will be listed below
-
Authors
Bervoets, Sander https://orcid.org/0009-0004-3958-7520
Duijkers, Lonneke https://orcid.org/0000-0002-1735-6340
Velde, Hedwig M. https://orcid.org/0000-0002-9408-5433
Corradi, Zelia https://orcid.org/0000-0002-2934-497X
van Oosten, Edwin M. https://orcid.org/0009-0000-4439-568X
Suárez-Herrera, Nuria https://orcid.org/0000-0002-3761-7325
Garanto, Alejandro https://orcid.org/0000-0001-5721-1560
Moreno-Pelayo, Miguel A. https://orcid.org/0000-0003-3839-5098
Pennings, Ronald J.E. https://orcid.org/0000-0001-5517-9683
Collin, Rob W.J. https://orcid.org/0000-0003-4347-6503
Vázquez-Domínguez, Irene https://orcid.org/0000-0001-9753-521X
-
Funding
Funding for this research was provided by:
Stichting Steunfonds Uitzicht (2022-06 PILOT)
Stichting Blindenhulp (N/A (direct request))
Stichting tot Verbetering van het Lot der Blinden (N/A (direct request))
Stichting voor Ooglijders (N/A (direct request))
HORIZON EUROPE Marie Sklodowska-Curie Actions (ARISTOS program No. 101081334)
- License Information
-
More Information
Article History
Received: 8 October 2025
Revised: 25 November 2025
Accepted: 7 December 2025
First Online: 13 January 2026
Change Date: 17 February 2026
Change Type: Update
Change Details: The original online version of this article was revised due to incorrect spelling error in the funding section . Now, it has been updated.
Declarations
:
: None of the authors have any conflict of interest to declare related to the content of this manuscript. For full transparency, R.W.J.C. is the Chief Executive Officer of Astherna B.V. R.W.J.C. and A.G. are inventors on several filed patents describing the use of antisense oligonucleotides (WO2013036105A1, WO2018109011A1, WO2020015959A1, WO2020115106A1, WO2021023863A1) to treat different genetic subtypes of inherited retinal diseases. These patents have been licensed by Radboudumc to ProQR Therapeutics B.V. or Astherna B.V. The remaining authors declare no conflicts of interest.
